KDR and cancer: In addition, DHX9 expression in most cancer types had an obvious positive correlation with several checkpoints, such as TGFBR1 (transforming growth factor-beta receptor 1), KDR (vascular endothelial growth factor receptor-2, VEGFR-2), and CD274 (PD-L1) (Figure 6A).